Rite Aid reported this week that its earnings per share totaled $0.04 last quarter, but the news did little to boost share prices, which have been sliding since the company
Problems surrounding an Indian company’s launch of generic versions of three blockbuster drugs have preserved millions in revenue for the brand-name makers, reports The Wall Street Journal. Meanwhile, Swiss pharmaceutical
The healthcare industry is in a “cost crisis,” fueling an increased interest in cost control, according to a presentation Thursday at the AHIP Institute in Seattle. “It’s called the Affordable
In a few years, the first blockbusters of the biotech age will begin to face generic competition. Big drugs like Amgen’s AMGN +2.54% Epogen and Neulasta, Roche and Biogen Idec’s
It wasn’t supposed to work this way, but since the Affordable Care Act took effect in January, Norton Hospital has seen its packed emergency room become even more crowded, with
Lets have a more visionary approach to reducing health costs. While most see the need to reduce health costs, wouldnt it be refreshing if our politicians and their advisers looked
A growing body of health care research shows significant waste can be found by looking at the overuse of certain medical services. “Cost is an indirect measure of overuse,” said
Medicare, the federal health insurance program for Americans 65 and older, could save $18 billion over the next 10 years if doctors switch to a less expensive drug to treat
As most patients in the American healthcare system know, its gotten harder and harder to maintain regular, detailed communication with your doctor. At least in terms of medication, pharmacists have
Generic drug companies are beyond the jurisdiction of the Patented Medicine Prices Review Board, the Federal Court has ruled in twin cases involving generic drug makers Ratiopharm (now Teva Canada)
